Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440622 | 1.00 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1900930 | 0.84 | ATM (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12362348 | 0.84 | ATM (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13684382 | 0.84 | ATM (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL688826 | 0.84 | ATM (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12618449 | 0.84 | ATM (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL7326307 | 0.82 | ATM (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14610905 | 0.82 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13663762 | 0.82 | MMP2 (0.42) | MMP2ANPEP | |
| Hydrochloric Acid SCHEMBL1303237 | 0.82 | ATM (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235555-A1 | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235555-A1 | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20130116178-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS | NOVARTIS AG (CH) | 2013-05-09 | — | — | US | disclosed |
| US-20130116178-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS | NOVARTIS AG (CH) | 2013-05-09 | — | — | US | disclosed |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-8188037-B2 | Microparticles comprising somatostatin analogues | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188037-B2 | Microparticles comprising somatostatin analogues | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20100029550-A1 | ORGANIC COMPOUNDS | LAMBERT OLIVIER | 2010-02-04 | — | — | US | disclosed |
| US-7648961-B2 | Accelerating the start of growth of quiescent follicles in non-menopausat women by administering somatostatin antagonist analog; reduces the risk of early menopause by preventing the accelerated activation of the follicular reserve which would make it more sensitive to chemotherapy agents or to radiation | PREGLEM S.A. (CH) | 2010-01-19 | — | — | US | disclosed |
| US-7648961-B2 | Accelerating the start of growth of quiescent follicles in non-menopausat women by administering somatostatin antagonist analog; reduces the risk of early menopause by preventing the accelerated activation of the follicular reserve which would make it more sensitive to chemotherapy agents or to radiation | PREGLEM S.A. (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080213330-A1 | Liquid solidification implants including biodegradable polymer; simplified prepatation; storage stable in prefilled syringe; negligible irritation, necrotic or toxic effects; Cushing's disease | LAMBERT OLIVIER | 2008-09-04 | — | — | US | disclosed |
| US-20080213330-A1 | Liquid solidification implants including biodegradable polymer; simplified prepatation; storage stable in prefilled syringe; negligible irritation, necrotic or toxic effects; Cushing's disease | LAMBERT OLIVIER | 2008-09-04 | — | — | US | disclosed |
| US-20070212418-A1 | Microparticles comprising somatostatin analogues | RECORDATI AG (CH) | 2007-09-13 | — | — | US | disclosed |
| US-20070212418-A1 | Microparticles comprising somatostatin analogues | RECORDATI AG (CH) | 2007-09-13 | — | — | US | disclosed |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-07-05 | — | — | US | disclosed |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-07-05 | — | — | US | disclosed |
| EP-1680139-B1 | USE OF SOMATOSTATIN OR ONE OF THE ANALOGS THEREOF FOR PRODUCING A MEDICAMENT SERVING TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | SOD CONSEILS RECH APPLIC (FR) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213330-A1 | Liquid solidification implants including biodegradable polymer; simplified prepatation; storage stable in prefilled syringe; negligible irritation, necrotic or toxic effects; Cushing's disease | CRH, GCG, SHBG | CHRM2 4330/4885CHRM4 4506/4885CHRM5 4485/4885 |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | SSTR5, SSTR3, SSTR4 | CHRM2 1401/4885CHRM4 1167/4885CHRM5 970/4885 |
| US-20140235555-A1 | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons | PGM2, PLG, RPL7 | CHRM2 4115/4885CHRM4 4760/4885CHRM5 3922/4885 |
| US-20100029550-A1 | ORGANIC COMPOUNDS | SLC16A3, SLC16A1, SSTR3 | CHRM2 1945/4885CHRM4 2013/4885CHRM5 2120/4885 |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | FSHR, GNRHR, SSTR3 | CHRM2 611/4885CHRM4 616/4885CHRM5 754/4885 |
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | FSHR, GNRHR, SSTR3 | CHRM2 611/4885CHRM4 616/4885CHRM5 754/4885 |
| US-20070212418-A1 | Microparticles comprising somatostatin analogues | SSTR5, SSTR3, SSTR4 | CHRM2 1401/4885CHRM4 1167/4885CHRM5 970/4885 |
| US-20130116178-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS | PGM2, PLG, RPL7 | CHRM2 4119/4885CHRM4 4739/4885CHRM5 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.